Published June 1, 2021
| Version v1
Journal article
Open
COVID-19 induced immunosuppression leading to secondary infection in a non-HIV patient
Creators
- 1. Vietnam National Hospital for Tropical Diseases, Ha Noi 10000, Vietnam
- 2. American University of the Caribbean, Cupe Coy, Saint Maarten, Kingdom of the Netherlands
- 3. Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam
- 4. R.C.S.M. Government Medical College, Kolhapur 41002, Maharashtra, India
- 5. School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
- 6. Radiology Department, Vinmec International Hospital, Ho Chi Minh City, Vietnam
- 7. Nassau University Medical Center, East Meadow, New York, United States
- 8. School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan
Description
Lymphopenia and immune dysfunction in COVID-19 is increasingly recognized and studied. This case report details a secondary infection following lymphopenia with CD4+ count drop in a COVID-19 patient with no history of immunosuppression or infection with HIV. The mechanism of lymphopenia, both CD4+ and CD8+ T cell count drops, in COVID-19 needs further study.
Notes
(Cite this article as: Ninh TT, Dong V, Loc LQ, Tsao T, Raut A, Karimzadeh S, et al. COVID-19 induced immunosuppression leading to secondary infection in a non-HIV patient. Minerva Respir Med 2021;60:59-61. DOI: 10.23736/S2784-8477.21.01914-3)
Files
2021 COVID-19 Case report non-HIV.pdf
Files
(296.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:bea8cb8eb0cc1ad68c2f6b92092d1c26
|
296.4 kB | Preview Download |
Additional details
References
- Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology 2020;160:261–8. PubMed https://doi.org/10.1111/imm.13223
- Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 2020;9:761–70. PubMed https://doi.org/10.1080/22221751.2020.1747363
- Fathi N, Rezaei N. Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol Int 2020;44:1792–7. PubMed https://doi.org/10.1002/cbin.11403
- Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75:1564–81. PubMed https://doi.org/10.1111/all.14364